C
Chao Wang
Researcher at Soochow University (Suzhou)
Publications - 731
Citations - 43903
Chao Wang is an academic researcher from Soochow University (Suzhou). The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 91, co-authored 561 publications receiving 32854 citations. Previous affiliations of Chao Wang include Huazhong University of Science and Technology & Agency for Science, Technology and Research.
Papers
More filters
Journal ArticleDOI
Functional Nanomaterials for Phototherapies of Cancer
Journal ArticleDOI
Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy
TL;DR: A therapeutic strategy that can eliminate primary tumours, inhibit metastases, and prevent tumour relapses is developed by combining adjuvant nanoparticle-based photothermal therapy with checkpoint-blockade immunotherapy, which offers a strong immunological memory effect, which can provide protection against tumour rechallenging post elimination of their initial tumours.
Journal ArticleDOI
Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China.
Lin Zhang,Feng Zhu,L. Xie,Chao Wang,Jing Wang,R. Chen,P. Jia,H.Q. Guan,L. Peng,Y. Chen,P. Peng,Peng Zhang,Q. Chu,Q. Shen,Yu Wang,S.Y. Xu,J.P. Zhao,Min Zhou +17 more
TL;DR: It is recommended that cancer patients receiving anti-tumour treatments should have vigorous screening for CO VID-19 infection and should avoid treatments causing immunosuppression or have their dosages decreased in case of COVID-19 co-infection.
Journal ArticleDOI
Drug Delivery with PEGylated MoS2 Nano‐sheets for Combined Photothermal and Chemotherapy of Cancer
Teng Liu,Chao Wang,Xing Gu,Hua Gong,Liang Cheng,Xiaoze Shi,Liangzhu Feng,Baoquan Sun,Zhuang Liu +8 more
TL;DR: MoS2 nanosheets functionalized with poly-ethylene glycol are for the first time used as a multifunctional drug delivery system with high drug loading capacities achieving excellent synergistic anti-tumor effect upon systemic administration.
Journal ArticleDOI
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.
Shuai Xia,Meiqin Liu,Chao Wang,Wei Xu,Qiaoshuai Lan,Siliang Feng,Feifei Qi,Linlin Bao,Lanying Du,Shuwen Liu,Chuan Qin,Fei Sun,Zhengli Shi,Yun Zhu,Shibo Jiang,Shibo Jiang,Lu Lu +16 more
TL;DR: EK1C4 was the most potent fusion inhibitor against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection with IC50s of 1.3 and 15.8 nM, about 241- and 149-fold more potent than the original EK1 peptide, respectively.